Tag Archive for: cancer immunotherapy
Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxImmunotherapy Drug Eradicates Aggressive Cancers in Clinical Trial
/in Clinical Trial, Metastatic, Phase 2/by MaxAPVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxA Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]
Phase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/in Clinical Trial, Metastatic, Phase 1/by MaxAI Platform Aims to Revolutionize Cancer Immunotherapy
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets
/in Immunotherapy, Preclinical Research/by MaxBreakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond
/in Immunotherapy, mRNA, Preclinical Research/by MaxA groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
Latest Posts
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
